Ann: Immutep granted US patent for IMP321, page-3

Immutep Ltd (IMM) reported the grant of a new patent by the United States Patent Office. This new patent provides intellectual property protection for Immutep’s method of treating cancer by the administration of a chemotherapy agent, and a plurality of doses of eftilagimod alpha (“efti” or “IMP321”) which is used to generate a monocyte mediated immune response. Importantly, the granted patent claims support the application of efti in Immutep’s ongoing AIPAC clinical trial in metastatic breast cancer

http://crweworld.com/article/news-provided-by-globenewswire/1025674/immutep-announces-united-states-patent-grant-for-eftilagimod-alpha-in-cancer